Why Cell-Free DNA Can Be a "Game Changer" for Lung Allograft Monitoring for Rejection and Infection

Area of Science:

• Transplantation immunology
• Biomarker discovery
• Genomic medicine

Background:

• Lung transplantation (LT) outcomes have improved short-term, but long-term allograft survival remains a challenge.
• Current monitoring relies on invasive biopsies, highlighting the need for non-invasive methods.
• Plasma donor-derived cell-free DNA (dd-cfDNA) is emerging as a potential non-invasive biomarker.

Purpose of the Study:

• To review the literature supporting the use of plasma dd-cfDNA for non-invasive surveillance of lung allograft injury.
• To discuss the role of dd-cfDNA in detecting rejection and infection post-LT.
• To identify future research directions for dd-cfDNA application in LT.

Main Methods:

• Literature review of studies investigating plasma dd-cfDNA in lung transplant recipients.
• Analysis of data associating dd-cfDNA levels with allograft injury, rejection, and infection.
• Exploration of ongoing research into dd-cfDNA methylation signatures and pathogen detection.

Main Results:

• Accumulating data links dd-cfDNA to acute rejection, antibody-mediated rejection, chronic lung allograft dysfunction, and infections.
• dd-cfDNA demonstrates strong performance in differentiating rejection and injury from stable allografts.
• Research is exploring dd-cfDNA methylation for tissue mapping and pathogen identification.

Conclusions:

• Clinical data supports the role of dd-cfDNA in monitoring lung allograft rejection and injury.
• Robust, diverse clinical trials are essential for widespread adoption of plasma dd-cfDNA for LT surveillance.
• Further research will refine dd-cfDNA's utility in assessing lung allograft health.